Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0149


Breast cancer: New key phase 3 trials data on sentinel node, recurrence biopsy and bevacizumab

Eleftheria Ignatiadou, M.D. and Charalabos Batsis, M.D.

Affiliation: Dr. Eleftheria Ignatiadou, and Charalabos Batsis, Assistant Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.


Since there is no abstract available we provide the first paragraph.

Data with major clinical utility for patients, physicians, medical and surgical oncologists were released at the ASCO 2010 meeting from large-scale phase 3 trials before the full publication. No prognostic significance had occult metastasis (micrometastasis) in sentinel node biopsy and no survival benefit was associated with bevacizumab treatment.

(Citation: Gastric & Breast Cancer 2011; 10(1): 43-46)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 8 February 2011